• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Revista Cubana de Hematología, Inmunología y Hemoterapia >Caracterizaci?3n de neonatos de madres con hipercoagulabilidad en r??gimen tromboprofil??ctico
【24h】

Caracterizaci?3n de neonatos de madres con hipercoagulabilidad en r??gimen tromboprofil??ctico

机译：菱形高凝血性母体母亲的特征

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: A decade ago, at the Institute of Hematology and Immunology, treatment of women with recurrent pregnancy losses due to hypercoagulability disorders began. Objective: Clinically characterize these infants and identify the adverse effects of thromboprophylactic therapy in newborns. Methods: A descriptive and transversal study was carried out between January 2014 and August 2017, which included 62 children of mothers with a diagnosis of thrombophilia who used during pregnancy, a thromboprophylaxis regimen with low molecular weight heparins and aspirin. All pregnant women were systematically evaluated in the Hemostasis and Obstetrics consultations of the Institute of Hematology and Immunology and Hospital Enrique Cabrera. Results: The majority of the neonates were born at term, with normal apgar and weights above 2,500 g. 82.3% of pregnant women started thromboprophylaxis with less than 5 weeks of gestational age. There were significant differences when the weights of the infants of the mothers who started the treatment early were compared with those who started it late. The type of thrombophilia and maternal age did not influence the weights of the neonates, but those cases with more severe symptoms had children of lower weight, which although it was not significant, requires observation. No newborn presented side effects to thromboprophylactic therapy. Conclusions: Infants born to mothers with thrombophilia who started thromboprophylaxis early were not different from those born to mothers without hypercoagulability.
机译：介绍：十年前，在血液学和免疫学研究所，由于高凝障碍因高凝患者而患有复发性妊娠损失的妇女。目的：临床表征这些婴儿，并确定血栓抑制治疗在新生儿的不良反应。方法：2014年1月至2017年8月间进行了描述性和横向研究，其中包括62名母亲儿童，诊断妊娠期间使用的血栓药粒细胞，具有低分子量肝素和阿司匹林的血栓血栓药中方案。所有孕妇都在系统性地评估了血液学和免疫学和医院恩克雷拉医院的止血和妇产基磋商。结果：大多数新生儿在术语出生，正常的APGAR和重量超过2,500克。 82.3％的孕妇开始血栓血管科血管缺陷，孕龄少于5周。当早期开始治疗的母亲的婴儿的重量与那些开始迟到的人进行比较有显着差异。血栓药毛细血管和产妇年龄的类型没有影响新生儿的重量，但这些症状更严重的病例有较轻的儿童，虽然它不显着，但需要观察。没有新生儿的副作用对血栓塑料治疗。结论：婴儿出生于患有血栓性血管缺陷的孕母亲早期与母亲的患者没有不同而没有高凝血性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号